These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 15665834)

  • 1. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
    Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
    Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
    Takimoto E; Champion HC; Belardi D; Moslehi J; Mongillo M; Mergia E; Montrose DC; Isoda T; Aufiero K; Zaccolo M; Dostmann WR; Smith CJ; Kass DA
    Circ Res; 2005 Jan; 96(1):100-9. PubMed ID: 15576651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats.
    Ferreira-Melo SE; Yugar-Toledo JC; Coelho OR; De Luca IM; Tanus-Santos JE; Hyslop S; Irigoyen MC; Moreno H
    Eur J Pharmacol; 2006 Aug; 542(1-3):141-7. PubMed ID: 16806160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
    Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
    Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
    Westermann D; Becher PM; Lindner D; Savvatis K; Xia Y; Fröhlich M; Hoffmann S; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2012 Nov; 107(6):308. PubMed ID: 23117837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.
    Senzaki H; Smith CJ; Juang GJ; Isoda T; Mayer SP; Ohler A; Paolocci N; Tomaselli GF; Hare JM; Kass DA
    FASEB J; 2001 Aug; 15(10):1718-26. PubMed ID: 11481219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5A as a target in cardiac disease.
    Doggrell SA
    Expert Opin Ther Targets; 2005 Oct; 9(5):1097-100. PubMed ID: 16185160
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.
    Hsu S; Nagayama T; Koitabashi N; Zhang M; Zhou L; Bedja D; Gabrielson KL; Molkentin JD; Kass DA; Takimoto E
    Cardiovasc Res; 2009 Feb; 81(2):301-9. PubMed ID: 19029137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra).
    Bouley R; Pastor-Soler N; Cohen O; McLaughlin M; Breton S; Brown D
    Am J Physiol Renal Physiol; 2005 Jun; 288(6):F1103-12. PubMed ID: 15644488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil.
    Zhu CB; Hewlett WA; Francis SH; Corbin JD; Blakely RD
    Eur J Pharmacol; 2004 Nov; 504(1-2):1-6. PubMed ID: 15507214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP.
    Wang M; Urenjak J; Fedele E; Obrenovitch TP
    Biochem Pharmacol; 2004 Apr; 67(8):1619-27. PubMed ID: 15041479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
    Rodríguez-Iturbe B; Ferrebuz A; Vanegas V; Quiroz Y; Espinoza F; Pons H; Vaziri ND
    Kidney Int; 2005 Nov; 68(5):2131-42. PubMed ID: 16221212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site.
    Lin CS; Chow S; Lau A; Tu R; Lue TF
    Biochem Biophys Res Commun; 2001 Jan; 280(3):693-9. PubMed ID: 11162576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.
    Nagayama T; Hsu S; Zhang M; Koitabashi N; Bedja D; Gabrielson KL; Takimoto E; Kass DA
    J Mol Cell Cardiol; 2009 Apr; 46(4):560-7. PubMed ID: 19159628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.
    Kim D; Aizawa T; Wei H; Pi X; Rybalkin SD; Berk BC; Yan C
    J Mol Cell Cardiol; 2005 Jan; 38(1):175-84. PubMed ID: 15623434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic GMP phosphodiesterase-5: target of sildenafil.
    Corbin JD; Francis SH
    J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772
    [No Abstract]   [Full Text] [Related]  

  • 20. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
    Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
    J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.